A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.

Trial Profile

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Minnelide (Primary)
  • Indications Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 19 Apr 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 19 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top